Inmune Bio Director Resigns
Ticker: INMB · Form: 8-K · Filed: May 30, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, filing
TL;DR
Inmune Bio director David Sidransky is out, filing includes financials.
AI Summary
On May 30, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of David L. Sidransky from its Board of Directors. The filing also includes financial statements and exhibits, but no specific financial figures or reasons for the resignation were disclosed in the provided text.
Why It Matters
The departure of a board member can signal changes in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board member changes can introduce uncertainty about company direction and stability.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- David L. Sidransky (person) — Resigning Board Director
- May 30, 2024 (date) — Date of Report
FAQ
Who is Inmune Bio, Inc.?
Inmune Bio, Inc. is a biotechnology company focused on biological products, incorporated in Nevada with its principal executive offices in Boca Raton, Florida.
What is the primary purpose of this 8-K filing?
This 8-K filing reports on Other Events and Financial Statements and Exhibits, specifically noting the resignation of a board member.
When was this report filed?
This report was filed on May 30, 2024.
Was a specific reason given for David L. Sidransky's resignation?
The provided text does not specify the reason for David L. Sidransky's resignation from the Board of Directors.
What is Inmune Bio, Inc.'s fiscal year end?
Inmune Bio, Inc.'s fiscal year ends on December 31.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-30 16:00:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0206941-8k_inmune.htm (8-K) — 23KB
- ea020694102ex99-1_inmune.htm (EX-99.1) — 12KB
- 0001213900-24-047951.txt ( ) — 210KB
- inmb-20240530_lab.xml (EX-101.LAB) — 33KB
- inmb-20240530_pre.xml (EX-101.PRE) — 22KB
- inmb-20240530.xsd (EX-101.SCH) — 3KB
- ea0206941-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On May 30, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on July 1, 2024. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated May 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: May 30, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2